1.066 INVESTIGATION ON THE RELATIONSHIP BETWEEN ANXIETY AND THE MOTOR SYMPTOMS OR NON-MOTOR SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE

2012 ◽  
Vol 18 ◽  
pp. S26
Author(s):  
Z. Liu ◽  
X. Huang ◽  
L. Sun ◽  
C. Cao ◽  
S. Yu ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Symptoms ◽  
The Relationship ◽  
Non Motor Symptoms

scholarly journals Frequency of non-motor symptoms in Peruvian patients with Parkinson's disease

2013 ◽  
Vol 71 (4) ◽  
pp. 216-219 ◽  
Author(s):  
Carlos Cosentino ◽  
Yesenia Nuñez ◽  
Luis Torres
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Progressive Increase ◽  
Motor Symptoms ◽  
Number Of Patients ◽  
Progression Of Disease ◽  
The Mean ◽  
Relationship Of ◽  
The Relationship ◽  
Non Motor Symptoms

Introduction: Non-motor symptoms in Parkinson's disease are often not well recognized in clinical practice. Non-motor symptoms questionnaire (NMSQuest) is a simple instrument that allows patients or caregivers to report non-motor symptoms in a practical manner. Objective: We attempted to determine the prevalence of non-motor symptoms in three hundred Parkinson's disease outpatients. Results: The mean total non-motor symptoms was 12.41, ranging from 0 to 27 of a maximum of 30. At least one was present in 99.3% of patients. A progressive increase in mean total score was observed across each 5-year interval. Depression domain scored the most “positive” answers while urinary and anxiety /memory were secondly and thirdly most prevalent respectively. Conclusion: The large number of patients included in this study allowed evaluation of the occurrence of non-motor symptoms in early and advanced disease in addition to the relationship of these kinds of symptoms with progression of disease.

scholarly journals Non–motor Symptoms in Parkinson’s Disease: It’s Relationship with Age of Onset, Duration and Stage of Disease and the Dose and Duration of Levodopa Usage

1970 ◽  
Vol 21 (1) ◽  
pp. 12-17
Author(s):  
M Ahmed Ali ◽  
Anisul Haque ◽  
AKM Anwarulla ◽  
Quamruddin Ahmad
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Psychiatric Symptoms ◽  
Disease Onset ◽  
Motor Symptoms ◽  
Autonomic Symptoms ◽  
Prolonged Duration ◽  
Relationship Of ◽  
The Relationship ◽  
Non Motor Symptoms

Parkinson's disease is a disease of motor manifestations but non-motor symptoms are also common in Parkinson's disease. Little emphasis is put on non-motor symptoms of PD and there is little data on the relationship of non-motor symptoms to different aspects of the patient and the disease. In this study the relationship of non-motor symptoms to age at onset, duration and stage of the disease, and dose and duration of levodopa use are studied.128 patients of PD were studied for non-motor symptoms. 111 patients had different types of sensory, autonomic or psychiatric symptoms. Sensory and autonomic symptoms were significantly more common in patients with early age of disease onset and more prolonged duration of the disease, but psychiatric symptoms had no relationship with these factors. In this study it was also found that the frequencies of non-motor symptoms were related to the stage of the disease, longer the duration of the disease more and more non-motor symptoms appear so that 100% patients in stage 5 of the disease had non-motor symptoms. Also sensory and autonomic symptoms were significantly more common in patients with longer duration and higher dose of levodopa use but psychiatric symptoms were significantly commoner in patients with prolonged duration of levodopa use but not to dose of levodopa used.   doi: 10.3329/taj.v21i1.3211 TAJ 2008; 21(1): 12-17

scholarly journals The Relationship Between Fatigue and Other Non-Motor Symptoms in Parkinson's Disease in Chinese Population

2017 ◽  
Vol 11 (3) ◽  
pp. 171-175 ◽  
Author(s):  
Jian Ding ◽  
Si-Ming Jiang ◽  
Yong-Sheng Yuan ◽  
Qing Tong ◽  
Li Zhang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Chinese Population ◽  
Motor Symptoms ◽  
The Relationship ◽  
Non Motor Symptoms

Catastrophizing mediates the relationship between non-motor symptoms and quality of life in Parkinson's disease

2019 ◽  
Vol 12 (4) ◽  
pp. 673-678 ◽  
Author(s):  
Sheera F. Lerman ◽  
Gila Bronner ◽  
Oren S. Cohen ◽  
Sandra Elincx-Benizri ◽  
Hanna Strauss ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Symptoms ◽  
The Relationship ◽  
Non Motor Symptoms

scholarly journals The main impacts of COVID-19 on parkinson’s disease patients

2021 ◽  
Author(s):  
Mariana Silva Regadas ◽  
Guilherme Albuquerque de Araújo Costa ◽  
Myrela Murad Sampaio
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Risk Factor ◽  
Old Age ◽  
Neurological Diseases ◽  
Severe Form ◽  
Initial Symptom ◽  
Motor Symptoms ◽  
The Relationship ◽  
Non Motor Symptoms

Background: COVID-19 patients with chronic diseases and comorbidities are more susceptible to the severe form of the infection. Neurological symptoms are reported by some patients infected by the virus and research seeks the relationship between the virus and neurological diseases, such as Parkinson’s Disease (PD). Objectives: To understand how COVID-19 and its effects affect patients with PD. Methods: Integrative review with search on Google Scholar, Scielo, PubMed and Science Direct platforms through an online scenario, selected articles from the years 2020 and 2021. Results: SARS-CoV-2 frequently undergo mutations, causes damage and inflammation. There are reports of symptoms such as anosmia, ageusia and headache. Anosmia stands out for its relationship with one initial symptom of PD, hyposmia. As the majority of PD patients are elderly and have comorbidities, there is a higher risk of being infected. Some patients with PD infected by the virus report worsening in motor and non-motor symptoms and such worsening can occur due to systemic inflammation, stress and the measures to contain the pandemic. Conclusions: PD is not a risk factor for COVID-19, however patients may experience worsening symptoms due to comorbidities, old age and stress caused by the pandemic. Strategies that reduce stress are options for maintaining the health of patients with PD.

scholarly journals The Parkinson’s Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson’s Disease in Patients and their Carers

2021 ◽  
pp. 1-15
Author(s):  
Eduardo Tolosa ◽  
Georg Ebersbach ◽  
Joaquim J. Ferreira ◽  
Olivier Rascol ◽  
Angelo Antonini ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Impact Assessment ◽  
Real World ◽  
European Countries ◽  
Life Questionnaire ◽  
Motor Symptoms ◽  
Non Motor Symptoms

Background: A greater understanding of the everyday experiences of people with Parkinson’s disease (PD) and their carers may help improve clinical practice. Objective: The Parkinson’s Real-world Impact assesSMent (PRISM) study evaluated medication use, health-related quality of life (HRQoL) and the use of healthcare resources by people with PD and their carers. Methods: PRISM is an observational cross-sectional study, in which people with PD and their carers completed an online survey using structured questionnaires, including the Parkinson’s Disease Quality of Life Questionnaire (PDQ-39), Non-Motor Symptoms Questionnaire (NMSQuest) and Zarit Burden Interview (ZBI). Results: Data were collected from 861 people with PD (mean age, 65.0 years; mean disease duration, 7.7 years) and 256 carers from six European countries. People with PD reported a large number of different co-morbidities, non-motor symptoms (mean NMSQuest score, 12.8), and impaired HRQoL (median PDQ-39 summary score, 29.1). Forty-five percent of people with PD reported at least one impulse control behaviour. Treatment patterns varied considerably between different European countries. Levodopa was taken in the last 12 months by 85.9% of participants, and as monotherapy by 21.8% . Carers, who were mostly female (64.8%) and the partner/spouse of the person with PD (82.1%), reported mild to moderate burden (mean ZBI total score, 26.6). Conclusions: The PRISM study sheds light on the lives of people with PD and those who care for them, re-emphasising the many challenges they face in everyday life. The study also provides insights into the current treatment of PD in Europe.

scholarly journals Study of cognitive impairment and genetic polymorphism of SLC41A1 (rs11240569 allele) in Parkinson’s disease in Upper Egypt: case-control study

2021 ◽  
Vol 57 (1) ◽  
Author(s):  
Hamdy N. El-Tallawy ◽  
Tahia H. Saleem ◽  
Wafaa M. Farghaly ◽  
Heba Mohamed Saad Eldien ◽  
Ashraf Khodaery ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Case Control Study ◽  
Case Control ◽  
Control Group ◽  
Motor Symptoms ◽  
And Control ◽  
Non Motor Symptoms ◽  
Control Study

Abstract Background Parkinson’s disease is one of the neurodegenerative disorders that is caused by genetic and environmental factors or interaction between them. Solute carrier family 41 member 1 within the PARK16 locus has been reported to be associated with Parkinson’s disease. Cognitive impairment is one of the non-motor symptoms that is considered a challenge in Parkinson’s disease patients. This study aimed to investigate the association of rs11240569 polymorphism; a synonymous coding variant in SLC41A1 in Parkinson’s disease patients in addition to the assessment of cognitive impairment in those patients. Results In a case -control study, rs11240569 single nucleotide polymorphisms in SLC41A1, genes were genotyped in 48 Parkinson’s disease patients and 48 controls. Motor and non-motor performance in Parkinson's disease patients were assessed by using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). The genotype and allele frequencies were compared between the two groups and revealed no significant differences between case and control groups for rs11240569 in SLC41A1 gene with P value .523 and .54, respectively. Cognition was evaluated and showed the mean ± standard deviation (SD) of WAIS score of PD patients 80.4 ± 9.13 and the range was from 61 to 105, in addition to MMSE that showed mean ± SD 21.96 ± 3.8. Conclusion Genetic testing of the present study showed that rs11240569 polymorphism of SLC41A1 gene has no significant differences in distributions of alleles and genotypes between cases and control group, in addition to cognitive impairment that is present in a large proportion of PD patients and in addition to the strong correlation between cognitive impairment and motor and non-motor symptoms progression.

scholarly journals Weeding through the haze: a survey on cannabis use among people living with Parkinson’s disease in the US

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Megan P. Feeney ◽  
Danny Bega ◽  
Benzi M. Kluger ◽  
A. Jon Stoessl ◽  
Christiana M. Evers ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Scientific Evidence ◽  
Symptom Control ◽  
Cannabis Use ◽  
Symptom Improvement ◽  
Motor Symptoms ◽  
The Us ◽  
Alternative Means ◽  
Non Motor Symptoms

AbstractSymptomatic management of Parkinson’s disease (PD) is complex and many symptoms, especially non-motor symptoms, are not effectively addressed with current medications. In the US, cannabis has become more widely available for medical and recreational use, permitting those in the PD community to try alternative means of symptom control. However, little is known about the attitudes towards, and experiences with, cannabis use among those living with PD. To address this shortcoming, we distributed an anonymous survey to 7,607 people with PD in January 2020 and received 1339 responses (17.6%). 1064 complete responses were available for analysis. Respondents represented 49 states with a mean age of 71.2 years (±8.3) and mean PD duration of 7.4 years (±6.2). About a quarter of respondents (24.5%) reported cannabis use within the previous six months. Age and gender were found to be predictors of cannabis use in this sample (Age OR = 0.95, 95% CI 0.93 to 0.97; Male OR = 1.44, 95% CI 1.03 to 2.03). Users reported learning about cannabis use from the internet/news (30.5%) and friends or other people with PD (26.0%). Cannabis users were more likely to report insufficient control of their non-motor symptoms with prescription medications than non-users (p = 0.03). Cannabis was primarily used for PD (63.6%) and was most often used to treat nonmotor symptoms of anxiety (45.5%), pain (44.0%), and sleep disorders (44.0%). However, nearly a quarter of users (23.0%) also reported they had stopped cannabis use in the previous six months, primarily due to a lack of symptom improvement (35.5%). Three quarters of respondents (75.5%) did not use cannabis, primarily because there was a lack of scientific evidence supporting efficacy (59.9%). Our results suggest that the lack of formal guidance or research evidence about cannabis for PD may in part underlie inconsistencies in both use and reported effectiveness.

Sign in / Sign up

Export Citation Format

Share Document